Global Overview of Different Versions of Tirzepatide

Tirzepatide is a novel hypoglycemic drug developed by Eli Lilly and Company. As a dual agonist of GIP/GLP-1 receptors, it has attracted worldwide attention. There are two main versions of tiltrotide: Mounjaro and Zepbound. 

Mounjaro: This is the hypoglycemic version of Tirzepatide, which was approved by the US FDA in May 2022 and is used to improve the blood sugar control of adult type 2 diabetes patients. In China, Mounjaro has also been approved by the State Drug Administration (NMPA) for blood glucose control in adults with type 2 diabetes. 

Zepbound: This is a weight loss version of Tirzepatide, approved by the US FDA on November 8, 2023, for chronic weight management. It is suitable for adult patients who are obese (BMI ≥ 28kg/m ^ 2) or overweight (BMI ≥ 24kg/m ^ 2) and have weight related comorbidities. On July 19, 2023, the product name Mounjaro was also approved by NMPA in China for long-term weight management. 

The sales of Tirzepatide have shown strong performance globally, with a total sales revenue of $2.96 billion in the first three quarters of 2023, a year-on-year increase of 1354%. This indicates a rapid growth in demand for tiltrotide in the global market, especially in the field of weight loss. 

In the Chinese market, the approval of tilporide provides new treatment options for patients with type 2 diabetes and obese or overweight patients who need weight management. With the launch of Tilpotide in China, it is expected that its sales in China will also show an increasing trend, further meeting the demand of Chinese patients for innovative drugs.

Comparison of product images of different versions of Mounjaro

Eli Lilly and Company is the original manufacturer of Tirzepatide, with a box of four injections

Eli Lilly and Company of Japan is also the original manufacturer of Tirzepatide, with two injections in a box

The Australia and Canada versions are in the form of multi dose vials and syringes